Experts call for new trials of hepatitis B drugs: evidence needed to identify first-line treatment.
Traynor
Kate
K
D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000517:prevention & control; D002986:Clinical Trials as Topic; D015975:Consensus Development Conferences, NIH as Topic; D024882:Drug Resistance, Viral / Q000187:drug effects; D005069:Evaluation Studies as Topic; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D017093:Liver Failure / Q000517:prevention & control; D008113:Liver Neoplasms / Q000517:prevention & control; D008396:Maryland; D017410:Practice Guidelines as Topic; D014481:United States
D000998:Antiviral Agents